We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
This briefing written at the invitation of Canada's Research-Based Pharmaceutical Companies (Rx&D) provides a further contribution to the current debate around IP rights for pharmaceuticals in Canada
